Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.77 |
| ▸ | AKT2 | P31751 | 4/20 | 0.77 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | PRKDC | P78527 | 1/20 | 0.60 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590246 | 1.00 | AKT1 (0.77) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL26137117 | 1.00 | AKT1 (0.77) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL30590141 | 0.94 | AKT1 (0.74) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL27196318 | 0.94 | AKT1 (0.74) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL26127832 | 0.93 | AKT1 (0.68) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL30682804 | 0.93 | AKT1 (0.70) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL26137119 | 0.93 | AKT1 (0.72) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL26957714 | 0.93 | AKT1 (0.70) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL30682819 | 0.93 | AKT1 (0.70) | AKT1AKT2AKT3PIK3CAPIK3CB | |
| SCHEMBL26128324 | 0.93 | AKT1 (0.72) | AKT1AKT2AKT3PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2024-04-18 | — | — | US | claimed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2024-04-18 | — | — | US | disclosed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192416-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124422-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PIK3CA, PIK3CD, PIK3R5 | AKT1 18/4885AKT2 17/4885AKT3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.